Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce ...

And rather than heading off to places with zero regulations, local firms—including a fledgling Biogen—stayed put. Over the decades, the Boston area became the world leader in biotech.

A federal commission is calling for $15 billion in new financing to re-enforce the United States’ biotech leadership amid ...

By Maggie Fick and Bhanvi Satija LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers ...